(Circulation. 1999;99:889-895.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
From Medical Clinic II, University Hospital Benjamin Franklin, Freie Universität Berlin (M.P., A.D., U.K., P.L.S., W.P., H.-P.S.); and the Department of Molecular Pathology, Institute for Pathology, Eberhard-Karls-Universität (R.K.), Tübingen, Germany.
Correspondence to Matthias Pauschinger, MD, Department of Cardiology, University Hospital Benjamin Franklin, Freie Universität Berlin, Hindenburgdamm 30, D-12200 Berlin, FRG.
| Abstract |
|---|
|
|
|---|
Methods and ResultsWe investigated enteroviral RNA replication versus enteroviral RNA persistence in endomyocardial biopsies of 45 patients with left ventricular dysfunction and clinically suspected myocarditis. Using reverse-transcriptase polymerase chain reaction in conjunction with Southern blot hybridization, we established a highly sensitive assay to specifically detect plus-strand versus minus-strand enteroviral RNA in the biopsies. Plus-strand enteroviral RNA was detected in endomyocardial biopsies of 18 (40%) of 45 patients, whereas minus-strand RNA as an indication of active enteroviral RNA replication was detected in only 10 (56%) of these 18 plus-strandpositive patients. Enteroviral RNA was not found in biopsies of the control group (n=26).
ConclusionsThese data demonstrate that a significant fraction of patients with left ventricular dysfunction and clinically suspected myocarditis had active enteroviral RNA replication in their myocardium (22%). Differentiation between patients with active viral replication and latent viral persistence should be particularly important in future studies evaluating different therapeutic strategies. In addition, molecular genetic detection of enteroviral genome and differentiation between replicating versus persistent viruses is possible in a single endomyocardial biopsy.
Key Words: myocarditis molecular biology polymerase chain reaction RNA viruses
| Introduction |
|---|
|
|
|---|
The development of highly sensitive molecular biological methods such as in situ hybridization and reverse-transcriptase polymerase chain reaction (RT-PCR) has made possible enteroviral RNA detection in human endomyocardial biopsies.4 5 6 7 None of the previous clinical studies, however, addressed the problem of differentiation between active viral replication and latent persistence of enteroviral genomes, which could have important consequences for the clinical course of the disease. This could be one possible explanation for the exactly opposite conclusions drawn by 2 recent studies on the prognostic significance of the presence of enteroviral RNA in patients with MC or dilated cardiomyopathy (DCM). One of these prospective studies6 came to the conclusion that the presence of enteroviral RNA in endomyocardial biopsies is a positive prognostic factor with respect to hemodynamic course and survival without the need for heart transplantation. In contrast, the other prospective study7 concluded from their data that detection of enteroviral RNA in the myocardium of MC or DCM patients is associated with an adverse prognosis and that the presence of enteroviral RNA is an independent predictor of unfavorable clinical outcome. This contradiction could be explained by different biological activities of the viral infection in the 2 patient collectives. To characterize the activity of the enteroviral infection in more detail, we developed an assay based on RT-PCR and Southern blot hybridization and conducted plus-strandspecific versus minus-strandspecific enteroviral RNA detection. Extensive controls were performed to definitely exclude the possibility of false-positive minus-strand enteroviral RNA detection, as observed in a previous report.8
| Methods |
|---|
|
|
|---|
55% or an
overall normal EF with regional wall motion disturbance in at
least 2 wall segments as analyzed independently by 2 different
observers) and clinically suspected MC were enrolled in the study. The
diagnosis of MC was suspected on the basis of a typical history with
recently occurring cardiac arrhythmia; electrocardiographic
changes; reduced exercise tolerance; or atypical chest pain (detailed
clinical data are listed in Table 1
|
|
Endomyocardial Biopsies
At least 5 endomyocardial right
ventricular biopsies were taken from each patient. One or
two biopsies were submitted to molecular biological analysis
for enteroviral RNA. The other biopsies were analyzed
histologically and immunohistologically
to assess myocardial inflammation. The analyses were performed
in blinded fashion by persons unaware of patient data and history.
Biopsies from explanted hearts of 26 patients having undergone heart
transplantation (coronary heart disease [n=24] and
valvular disease [n=2]) served as negative controls. These
biopsies obtained at the time of heart transplantation were immediately
frozen in liquid nitrogen in the operating room to preserve messenger
and enteroviral RNA, respectively.
All procedures were performed in accordance with ethical standards and with the Helsinki Declaration of 1975. All patients gave informed consent for all of the invasive studies performed.
Histology and Immunohistology
Hematoxylin-eosin staining of paraffin sections was carried out
and analyzed according to standard methods.10 In
addition, cryostat sections were analyzed for infiltrating CD3
T-lymphocytes as published previously.11
RT-PCR and Southern Blot Analysis
All patients were included in the study prospectively before
completion of RT-PCR. One hundred nanograms total RNA12 of
each biopsy was transcribed into cDNA by MMLV reverse transcriptase
with random primers according to the supplier's recommendations (BRL).
Identical reactions containing no RNA template served as negative
controls and were consistently negative in all further
analyses. In separate experiments to determine the polarity of
the RNA, the cDNA of plus-strand enteroviral RNA was synthesized in a
20-µL solution containing 100 ng total RNA, 0.5 mmol/L
deoxynucleotide triphosphate, 0.06 pmol 3' coxsackie
primer, and 200 IU MMLV reverse transcriptase as described by the
manufacturer. The cDNA of minus-strand enteroviral RNA was synthesized
in the same way using 0.06 pmol 5' coxsackie primer instead of 3'
coxsackie primer (Table 2
). The cDNA thus
obtained was heated to 95°C for 30 minutes to inactivate
the reverse transcriptase activity and then incubated at 0°C for 10
minutes (Figure 1
). Each sample was
directly used in the RT-PCR with a 35-cycle program consisting of
denaturation at 94°C for 45 seconds, annealing at 61°C for 45
seconds, and extension at 72°C for 90 seconds in a standard PCR
buffer (1.5 mmol/L MgCl2, 50 mmol/L
KCl, 10 mmol/L TRIS-HCl, pH 8.3, 0.01% gelatin, 0.3 µmol/L
primers, 0.2 mmol/L dNTPs, 2.5 U
Taq-polymerase).13 The
oligonucleotide sequences chosen for enteroviral RNA
amplification are located in the consensus enteroviral sequences of the
noncoding 5' region and therefore present a high degree of group
specificity (Table 2
) and detect different types of
enteroviruses (coxsackievirus B1-B6, coxsackievirus A9, poliovirus 1,
ECHO-viruses 11 and 12).3 14 The amplified RT-PCR
product has a length of 314 bp. A cloned cDNA of coxsackievirus B3
served as a positive control.15 For further
positive controls, coamplification of endogenous ß-actin
and enteroviral RNA was carried out with specific ß-actin primers
(Table 2
).16 The RT-PCR products were separated
by gel electrophoresis and stained with ethidium bromide in standard
methods. The ß-actin bands were then visualized by ultraviolet light
(254 nm) with a length of 461 bp (molecular weight marker pBR328
DNA
BglI+pBR328 DNA
HinfI) (Figure 2
). This was followed by Southern blot
hybridization with a 5' P32-labeled
oligonucleotide (cox hyb:
5'-CGAAGTAGTTGG-CCGGATAAC-3') in standard
methods3 14 (membranes were washed twice in 6xSSC
and 0.1% SDS at room temperature and in 0.1x SSC and 0.1% SDS for 30
minutes at 50°C) (Figure 2
).
|
|
|
Strand-Specific Enteroviral RNA Detection
Throughout the detection procedure for minus-strand enteroviral
RNA, complete inactivation of the reverse transcriptase after cDNA
synthesis was essential for strand specificity. Therefore, the
specificity of the strand-specific enteroviral RNA detection assay was
tested by using T7 and SP6, respectively, in in vitro synthesized sense
and antisense transcripts of coxsackie B3 enteroviral RNA from the 5'
noncoding region (577 bp). As a control for inactivation of the reverse
transcriptase, enteroviral RNA transcripts were incubated with the 3'
coxsackie primer in the reverse transcription mixture (Figure 1
). This reverse transcription mixture was boiled for 0 to 60
minutes to inactivate the enzyme activity of the reverse
transcriptase. After the enzyme heat inactivation, this mixture was
amplified by 35 cycles of RT-PCR with the 3' and 5' coxsackie primers,
respectively. Positive signals for minus-strand RNA were completely
absent after boiling for more than 20 minutes in all cases. The
positive signal for minus-strand RNA until 15 minutes of boiling
appears to be the result of residual reverse transcriptase activity in
the RT-PCR reaction mix. Therefore, all samples analyzed in the
strand-specific detection assay were boiled for 30 minutes after
first-strand cDNA synthesis to definitely avoid false-positive results
(Figure 3
).
|
Statistical Analysis
All values are expressed as mean±SD.
| Results |
|---|
|
|
|---|
Histology and Immunohistology
The histological investigation of the
endomyocardial biopsies resulted in the diagnosis
of borderline MC in 6 (13%) of the studied patients.
Immunohistological analysis of the
endomyocardial biopsies showed increased mean CD3
T-lymphocytes (3.3±6.9 T-lymphocytes/HPF) (Table 1
).
Strand-Specific Enteroviral RNA Detection
RT-PCR combined with Southern blot hybridization was used to
examine the myocardial biopsies of all 45 patients with left
ventricular dysfunction and clinically suspected MC
for plus-strand and minus-strand enteroviral RNA. At the same time,
26 samples from the control population were examined. In all 71
amplifications, the internal ß-actinpositive control was visible in
the ethidium-bromidestained agarose gel under ultraviolet light
(Figure 2
). This excludes false-negative biopsy results caused
by degradation of extracted RNA. In patients with the left
ventricular dysfunction and clinically suspected diagnosis
of MC, plus-strand enteroviral RNA was detected in 18 (40%) cases. In
ten (56%) of these 18 plus-strandpositive patients, detection of
minus-strand enteroviral RNA was possible. These data demonstrate that
a significant fraction of patients (22%) with left
ventricular dysfunction and clinically suspected MC had
active enteroviral RNA replication in the myocardium.
In contrast, all 26 patients from a control group were negative when myocardial tissue was examined for enteroviral RNA by RT-PCR.
| Discussion |
|---|
|
|
|---|
After introduction of highly sensitive molecular biological methods in the diagnosis of viral heart disease, the detection of enteroviral RNA in human endomyocardial biopsies became possible.4 5 6 7 However, the clinical relevance of enteroviral RNA detection in endomyocardial biopsies of patients with DCM or MC is highly controversial, as discussed in 2 recently published reports.6 7 The hemodynamic status of the enrolled patients in both studies was comparable with respect to EF and LVEDD. However, despite the comparable degree of left ventricular dysfunction in both studies as a well known parameter of prognosis in chronic heart failure,17 18 the clinical course of the analyzed patients in both studies was the opposite. Nevertheless, 1 study6 concluded that the presence of enteroviral RNA is a favorable prognostic factor, whereas the other study7 found it to be associated with an adverse outcome. These controversial results of the 2 studies, despite comparable hemodynamic impairment of left ventricular dysfunction, might possibly be explained by different biological activities of viral heart disease.
On the basis of our knowledge on enterovirus biology, an assay distinguishing latent persistence and active replication could possibly resolve this problem. Whether or not this differentiation is sufficient to completely resolve the issue, this kind of more thorough analysis should be incorporated in future prospective studies of MC. Moreover, distinction of latent persistence versus active enteroviral replication in the myocardium might also improve our understanding of this apparently highly dynamic human viral disease. Considering the controversial results of several small therapy trials of human MC,6 19 20 21 it seems appropriate to characterize as exactly as possible the disease state of patients to be assigned to one or another treatment regime. According to the Dallas10 criteria, 13% of the biopsies of our patients with left ventricular dysfunction and clinically suspected MC were diagnosed as having borderline MC. This incidence of histologically positive results in patients with clinically suspected MC is comparable with the Myocarditis Treatment Trial.19 In this trial, active plus borderline MC was diagnosed histologically by the pathologists at the participating centers in 10% of patients with clinically suspected MC. However, a later review by an independent pathology panel of 107 enrolled endomyocardial biopsies came to the conclusion that only 64% actually met the Dallas criteria for active MC or borderline MC.10 19 This emphasizes the considerable difficulties associated with the histological diagnosis of MC. In part, the low incidence of histologically positive results in patients with clinically suspected MC19 may be due to the fact that MC is often focal and therefore missed by the standard biopsy procedure. In addition, cellular infiltrates are sparse, and by using standard histological techniques it is difficult to distinguish between noninflammatory cells (for example, fibroblasts or pericytes) and infiltrating lymphocytes.22 For this reason, we additionally used immunohistological techniques to identify low-level lymphocytic infiltrates in myocardial biopsies.11 Although 87% of our endomyocardial biopsies classified as negative according to the Dallas criteria showed inflammatory cell infiltrates, immunohistology did not help to distinguish between patients with and those without enteroviral replicative intermediates.
False-positive minus-strand detection caused by reverse transcriptase activity during RT-PCR was ruled out in our study by exhaustive inactivation of the enzyme by boiling for 30 minutes at the end of the reverse transcription. In addition, strand specificity was documented by analyzing in vitro transcribed cloned enteroviral cRNA of positive polarity and negative polarity, respectively, as templates. The plus strand was transcribed from the SP6 promotor and the minus strand from the T7 promotor of our enteroviral cDNA clone. Former problems8 with strand specificity were thus eliminated. Furthermore, our assay system unequivocally differentiated between virus-positive (strong signal) and virus-negative patients (no signal). Intermediate results as previously reported for the slot blot assay described by Why et al7 with a defined cut-off value of the hybridization index were never observed in any of our patients.
Summary
Our results show that a significant fraction of patients (22%)
with left ventricular dysfunction and clinically suspected
MC had active enteroviral RNA replication in their
myocardium. Therefore, molecular genetic differentiation
between active viral replication and latent viral persistence should be
considered in the design of prospective clinical studies on the
clinical course of this apparently dynamic viral disease. This
differentiation should be particularly important in future studies
evaluating different therapeutic strategies.
Received July 31, 1998; revision received November 4, 1998; accepted November 11, 1998.
| References |
|---|
|
|
|---|
2. Woodruff JF. Viral myocarditis: a review. Am J Pathol. 1980;101:425484.[Medline] [Order article via Infotrieve]
3. Hohenadl C, Klingel K, Mertsching J, Hofschneider PH, Kandolf R. Strand-specific detection of enteroviral RNA in myocardial tissue by in situ hybridization. Moll Cell Probes. 1991;5:1120.
4. Bowles NE, Richardson PJ, Olson EG, Archard LC. Detection of coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet. 1986;17:11201123.
5.
Jin O, Sole MJ, Butany JW, Chia WK, McLaughlin PR, Liu
P, Liew CC. Detection of enterovirus RNA in myocardial biopsies from
patients with myocarditis and cardiomyopathy using
gene amplification by polymerase chain reaction.
Circulation. 1990;82:816.
6. Figulla HR, Stille-Siegener M, Mall G, Heim A, Kreuzer H. Myocardial enterovirus infection with left ventricular dysfunction: a benign disease compared with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;25:11701175.[Abstract]
7.
Why HJ, Meany BT, Richardson PJ, Olsen EG, Bowles NE,
Cunningham L, Freeke CA, Archard LC. Clinical and prognostic
significance of detection of enteroviral RNA in the
myocardium of patients with myocarditis or dilated
cardiomyopathy. Circulation. 1994;89:25822589.
8. McGuinness PH, Bishop GA, McCaughan GW, Towbridge R, Gowans EJ. False detection of negative-strand hepatitis C virus RNA. Lancet. 1994;343:551552.[Medline] [Order article via Infotrieve]
9. Dodge HT, Sheehan FH. Quantitative contrast angiography for assessment of ventricular performance in heart disease. J Am Coll Cardiol. 1983;1:7381.[Abstract]
10. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JF, Olsen EG, Schoen FJ. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1:314.[Medline] [Order article via Infotrieve]
11.
Kühl U, Noutsias M, Seeberg B, Schultheiss H-P.
Immunohistological evidence for a chronic
intramyocardial inflammatory process in dilated
cardiomyopathy. Heart. 1996;75:295300.
12. Auffray C, Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem. 1980;107:303314.[Medline] [Order article via Infotrieve]
13.
Saiki RK, Gelfand DH, Stoffel S, Scharf SJ,
Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer directed enzymatic
amplification of DNA with a thermostable DNA polymerase.
Science. 1988;239:487491.
14.
Klump WM, Bergmann I, Muller BC, Ameis D, Kandolf R.
Complete nucleotide sequence of infectious Coxsackievirus
B3 cDNA: two initial 5' uridine residues are regained during
plus-strand RNA synthesis. J Virol. 1990;64:15731583.
15.
Kandolf R, Hofschneider PH. Molecular cloning of the
genome of a cardiotropic Coxsackie B3 virus: full-length
reverse-transcribed recombinant cDNA generates infectious virus in
mammalian cells. Proc Natl Acad Sci U S A. 1985;82:48184822.
16.
Nakajiama-Iijma S, Hamada H, Reddy P, Kakznaga T.
Molecular structure of the human cytoplasmic beta-actin gene:
interspecies homology of sequences in the introns. Proc Natl Acad
Sci U S A. 1985;82:61336137.
17. Jiulliére Y, Danchin N, Briancon S, Khalife K, Ethévenot G, Balaud A, Gilgenkrantz JM, Pernot C, Cherrier F. Dilated cardiomyopathy: long-term follow-up and predictors of survival. Int J Cardiol. 1988;21:269277.[Medline] [Order article via Infotrieve]
18.
Diaz RA, Obasohan A, Oakley CM. Prediction of outcome
in dilated cardiomyopathy. Br Heart
J. 1987;58:393399.
19.
Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus
BM, Billingham ME, Moon TE, and the Myocarditis Treatment Trial
Investigators. A clinical trial of immunosuppressive therapy for
myocarditis. N Engl J Med. 1995;333:269275.
20. Schultheiss H-P, Kühl U, Janda I, Schannwell M, Strauer BE. Immunosuppressive therapie in myocarditis. Herz. 1992;17:112121.[Medline] [Order article via Infotrieve]
21. Hobbs RE, Pelegrin D, Ratliff NB. Lymphocytic myocarditis and dilated cardiomyopathy: treatment with immunosuppressive agents. Cleve Clin J Med. 1989;56:628635.[Medline] [Order article via Infotrieve]
22. Billingham ME. Acute myocarditis: is sampling error a contra-indication for diagnostic biopsies? J Am Coll Cardiol. 1989;14:921922.Enteroviruses are considered important factors for the development of myocarditis. All previous studies dealing with the detection of enteroviral RNA have not analyzed the biological activity (latent persistence versus active replication) of this apparently dynamic viral human disease. In this study, we demonstrated that a significant number of patients with left ventricular dysfunction and clinically suspected myocarditis had active enteroviral RNA replication in the myocardium (22%). Therefore, molecular genetic differentiation between active viral replication and latent viral persistence should be incorporated in the design of prospective clinical studies, in particular those evaluating different therapeutic strategies.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
A. Frustaci, M. A. Russo, and C. Chimenti Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study Eur. Heart J., June 25, 2009; (2009) ehp249v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Holzmann, A. Nicko, U. Kuhl, M. Noutsias, W. Poller, W. Hoffmann, A. Morguet, B. Witzenbichler, C. Tschope, H.-P. Schultheiss, et al. Complication Rate of Right Ventricular Endomyocardial Biopsy via the Femoral Approach: A Retrospective and Prospective Study Analyzing 3048 Diagnostic Procedures Over an 11-Year Period Circulation, October 21, 2008; 118(17): 1722 - 1728. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dennert, H. J. Crijns, and S. Heymans Acute viral myocarditis Eur. Heart J., September 1, 2008; 29(17): 2073 - 2082. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Baughman Diagnosis of Myocarditis: Death of Dallas Criteria Circulation, January 31, 2006; 113(4): 593 - 595. [Full Text] [PDF] |
||||
![]() |
U. Kuhl, M. Pauschinger, B. Seeberg, D. Lassner, M. Noutsias, W. Poller, and H.-P. Schultheiss Viral Persistence in the Myocardium Is Associated With Progressive Cardiac Dysfunction Circulation, September 27, 2005; 112(13): 1965 - 1970. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-S. Kim, S. Tracy, W. Tapprich, J. Bailey, C.-K. Lee, K. Kim, W. H. Barry, and N. M. Chapman 5'-Terminal Deletions Occur in Coxsackievirus B3 during Replication in Murine Hearts and Cardiac Myocyte Cultures and Correlate with Encapsidation of Negative-Strand Viral RNA J. Virol., June 1, 2005; 79(11): 7024 - 7041. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pauschinger, S. Rutschow, K. Chandrasekharan, D. Westermann, A. Weitz, L. P. Schwimmbeck, H. Zeichhardt, W. Poller, M. Noutsias, J. Li, et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis Association with reduced myocardial interleukin-1{beta} and MMP-8 expression and a modulated immune response Eur J Heart Fail, June 1, 2005; 7(4): 444 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Vallbracht, P. L. Schwimmbeck, U. Kuhl, U. Rauch, B. Seeberg, and H.-P. Schultheiss Differential Aspects of Endothelial Function of the Coronary Microcirculation Considering Myocardial Virus Persistence, Endothelial Activation, and Myocardial Leukocyte Infiltrates Circulation, April 12, 2005; 111(14): 1784 - 1791. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Kuhl, M. Pauschinger, M. Noutsias, B. Seeberg, T. Bock, D. Lassner, W. Poller, R. Kandolf, and H.-P. Schultheiss High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With "Idiopathic" Left Ventricular Dysfunction Circulation, February 22, 2005; 111(7): 887 - 893. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Tschope, C.-T. Bock, M. Kasner, M. Noutsias, D. Westermann, P.-L. Schwimmbeck, M. Pauschinger, W.-C. Poller, U. Kuhl, R. Kandolf, et al. High Prevalence of Cardiac Parvovirus B19 Infection in Patients With Isolated Left Ventricular Diastolic Dysfunction Circulation, February 22, 2005; 111(7): 879 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Vallbracht, P. L. Schwimmbeck, U. Kuhl, B. Seeberg, and H.-P. Schultheiss Endothelium-Dependent Flow-Mediated Vasodilation of Systemic Arteries Is Impaired in Patients With Myocardial Virus Persistence Circulation, November 2, 2004; 110(18): 2938 - 2945. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dorner, D. Xiong, K. Couch, T. Yajima, and K. U. Knowlton Alternatively Spliced Soluble Coxsackie-adenovirus Receptors Inhibit Coxsackievirus Infection J. Biol. Chem., April 30, 2004; 279(18): 18497 - 18503. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Calabrese and G. Thiene Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects Cardiovasc Res, October 15, 2003; 60(1): 11 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Kuhl, M. Pauschinger, T. Bock, K. Klingel, C. P. L. Schwimmbeck, B. Seeberg, L. Krautwurm, W. Poller, H.-P. Schultheiss, and R. Kandolf Parvovirus B19 Infection Mimicking Acute Myocardial Infarction Circulation, August 26, 2003; 108(8): 945 - 950. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Noutsias, M. Pauschinger, H.-P. Schultheiss, and U. Kuhl Cytotoxic perforin+ and TIA-1+ infiltrates are associated with cell adhesion molecule expression in dilated cardiomyopathy Eur J Heart Fail, August 1, 2003; 5(4): 469 - 479. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Kuhl, M. Pauschinger, P. L. Schwimmbeck, B. Seeberg, C. Lober, M. Noutsias, W. Poller, and H.-P. Schultheiss Interferon-{beta} Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction Circulation, June 10, 2003; 107(22): 2793 - 2798. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Poller, H. Fechner, M. Noutsias, C. Tschoepe, M. Pauschinger, and H.-P. Schultheiss The molecular basis of cardiotropic viral infections Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I18 - I30. [Abstract] [PDF] |
||||
![]() |
M. Noutsias, M. Pauschinger, H.-P. Schultheiss, and U. Kuhl Advances in the immunohistological diagnosis of inflammatory cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I54 - I62. [Abstract] [PDF] |
||||
![]() |
A. Frustaci, M. Pieroni, and C. Chimenti Immunosuppressive therapy in inflammatory cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I69 - I72. [Abstract] [PDF] |
||||
![]() |
U. Kuhl, M. Pauschinger, M. Noutsias, J.-F. Kapp, and H.-P. Schultheiss Diagnosis and treatment of patients with virus induced inflammatory cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I73 - I80. [Abstract] [PDF] |
||||
![]() |
J. Li, P. Lothar Schwimmbeck, C. Tschope, S. Leschka, L. Husmann, S. Rutschow, F. Reichenbach, M. Noutsias, U. Kobalz, W. Poller, et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction Cardiovasc Res, November 1, 2002; 56(2): 235 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Feuer, I. Mena, R. Pagarigan, M. K. Slifka, and J. L. Whitton Cell Cycle Status Affects Coxsackievirus Replication, Persistence, and Reactivation In Vitro J. Virol., March 27, 2002; 76(9): 4430 - 4440. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Noutsias, H. Fechner, H. de Jonge, X. Wang, D. Dekkers, A.B. Houtsmuller, M. Pauschinger, J. Bergelson, R. Warraich, M. Yacoub, et al. Human Coxsackie-Adenovirus Receptor Is Colocalized With Integrins {alpha}v{beta}3 and {alpha}v{beta}5 on the Cardiomyocyte Sarcolemma and Upregulated in Dilated Cardiomyopathy: Implications for Cardiotropic Viral Infections Circulation, July 17, 2001; 104(3): 275 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
M T Kearney, J M Cotton, P J Richardson, and A M Shah Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management Postgrad. Med. J., January 1, 2001; 77(903): 4 - 10. [Abstract] [Full Text] |
||||
![]() |
S. Fujioka, Y. Kitaura, A. Ukimura, H. Deguchi, K. Kawamura, T. Isomura, H. Suma, and A. Shimizu Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1920 - 1926. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kishimoto, N. Takamatsu, H. Kawamata, H. Shinohara, and H. Ochiai Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1979 - 1984. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dorner, M. Pauschinger, P. L. Schwimmbeck, U. Kuhl, and H.-P. Schultheiss The shift in the myocardial adenine nucleotide translocator isoform expression pattern is associated with an enteroviral infection in the absence of an active T-cell dependent immune response in human inflammatory heart disease J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1778 - 1784. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, T. Bourlet, L. Andreoletti, J.-F. Mosnier, T. Peng, Y. Yang, L. C. Archard, B. Pozzetto, and H. Zhang Enteroviral Capsid Protein VP1 Is Present in Myocardial Tissues From Some Patients With Myocarditis or Dilated Cardiomyopathy Circulation, January 25, 2000; 101(3): 231 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
Active Enteroviral RNA Replication in Patients with Suspected Myocarditis Journal Watch Cardiology, May 21, 1999; 1999(521): 14 - 14. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |